Home / Health / NHS Adopts New Heart Failure Drug, Kerendia
NHS Adopts New Heart Failure Drug, Kerendia
17 Jul
Summary
- NICE recommends Bayer's Kerendia for chronic heart failure patients.
- The drug targets patients with preserved or mildly reduced ejection fraction.
- Kerendia aims to improve quality of life and reduce hospitalizations.
In England, the National Institute for Health and Care Excellence (NICE) has recommended Bayer's non-steroidal heart failure drug, Kerendia (finerenone), for use within the National Health Service (NHS). This decision is significant as heart failure remains a leading cause of avoidable hospitalizations in the country.
An estimated 280,000 individuals across England are now eligible for Kerendia treatment. The drug is intended for patients diagnosed with chronic heart failure (CHF) who have preserved or mildly reduced ejection fraction. Kerendia functions by reducing inflammation and scarring in the heart wall and lessening the kidneys' sodium retention.
This recommendation expands Kerendia's accessibility, as it was previously approved by NICE in 2023 for certain patients with stage 3 or 4 chronic kidney disease linked to type 2 diabetes. The drug's non-steroidal nature differentiates it from existing NHS medications like spironolactone and eplerenone, potentially allowing for wider application.
NICE anticipates final guidance in August 2026. The inclusion of Kerendia in the NHS treatment arsenal, alongside SGLT2 inhibitors and older MRAs, is expected to improve patient outcomes. Health officials believe the drug may also contribute to cost savings by decreasing the need for unplanned emergency hospital treatments.
